On December 13, 2022 Biosion USA, Inc. (Biosion), a global R&D biotechnology company, reported an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc. (Nasdaq: IMGN), a leader in developing next generation ADCs (Press release, Biosion, DEC 13, 2022, View Source [SID1234625164]). In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about our new joint research effort with ImmunoGen, a world-renowned leader in ADCs," said Hugh Davis, Ph.D., Chief Operating Officer, and President of Biosion USA, Inc. "This collaboration will take advantage of the strengths of each company; ImmunoGen’s expertise in linkers and payloads combined with Biosion’s SynTracer HT endocytosis platform with the goal of identifying novel treatments for solid tumor cancers."